Answers are grounded in this paper and cite their sources.
The results provide a proof of principle that etanercept can be an attractive therapeutic strategy for refractory innate immune RSA.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: